Immunotherapy for gastric cancer: Advances and challenges

Abstract

Gastric cancer (GC) ranks among the leading causes of cancer-related mortality globally. Often, its initial stages manifest subtly, and the infrequency of routine screenings contributes to late diagnoses in many cases. Systemic treatments for GC include chemotherapy, targeted therapy, and immunotherapy, among which immunotherapy is the first-line standard treatment for advanced GC. In recent years, immunotherapy has seen notable advancements, as evidenced by the Food and Drug Administration’s approval of drugs such as nivolumab and pembrolizumab for GC treatment. Additionally, several other drugs are currently under rigorous preclinical and clinical investigation. This review aims to shed light on the recent advancements in immunotherapy for GC, particularly emphasizing the insights gained from phase 2/3 clinical trials that assess the efficacy, safety, and promise of various immunotherapeutic modalities, including immune checkpoint inhibitors, CAR-T-cell therapies, and cancer vaccines, in enhancing patient outcomes. Moreover, this review delves into the intricate immunological framework of GC, focusing on the tumor microenvironment, interactions among immune cells, and the roles of immune checkpoints such as PD-L1. We also address the hurdles and prospective paths forward in the realm of immunotherapy for GC, offering fresh viewpoints on potential therapeutic approaches in this evolving domain.

Keywords

gastric cancer / immunotherapy / phase 2/3 / resistance / tumor microenvironment

References

[1] WangJ, QinD, TaoZ, et al. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer. Front Immunol. 2022;13:1056932.

[2] YangJ, SuH, ChenT, et al. Development and validation of nomogram of peritoneal metastasis in gastric cancer based on simplified clinicopathological features and serum tumor markers. BMC Cancer. 2023;23(1):64.

[3] SungH, FerlayJ, SiegelRL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.

[4] NormileN. Biomedical research. An Asian tiger’s bold experiment. Science. 2007;316(5821):38-41.

[5] WuJQ, ZhaiJ, LiCY, et al. Patient-derived xenograft in zebrafish embryos: a new platform for translational research in gastric cancer. J Exp Clin Cancer Res. 2017;36(1):160.

[6] IlicM, IlicI. Epidemiology of stomach cancer. World J Gastroenterol. 2022;28(12):1187-1203.

[7] TanYK, Fielding JWL. Early diagnosis of early gastric cancer. Eur J Gastroenterol Hepatol. 2006;18(8):821-829.

[8] ZhongY, KangW, HuH, LiW, ZhangJ, Tian Y. Lobaplatin-based prophylactic hyperthermic intraperitoneal chemotherapy for T4 gastric cancer patients: a retrospective clinical study. Front Oncol. 2023;13:995618.

[9] BiagioniA, Skalamera I, PeriS, et al. Update on gastric cancer treatments and gene therapies. Cancer Metastasis Rev. 2019;38(3):537-548.

[10] SongZ, WuY, YangJ, Yang D, FangX. Progress in the treatment of advanced gastric cancer. Tumor Biol. 2017;39(7):1010428317714626.

[11] LiangX, ZhuJ, LiY, et al. Treatment strategies for metastatic gastric cancer: chemotherapy, palliative surgery or radiotherapy? Future Oncol. 2020;16(5):91-102.

[12] BodL, KyeY-C, ShiJ, et al. B-cell-specific checkpoint molecules that regulate anti-tumour immunity. Nature. 2023;619(7969):348-356.

[13] YangF, HeZ, DuanH, et al. Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40. Nat Commun. 2021;12(1):3424.

[14] HauthF, HoAY, FerroneS, Duda DG. Radiotherapy to enhance chimeric antigen receptor T-cell therapeutic efficacy in solid tumors: a narrative review. JAMA Oncol. 2021;7(7):1051-1059.

[15] HuD, ZhangW, TangJ, Zhou Z, LiuX, ShenY. Improving safety of cancer immunotherapy via delivery technology. Biomaterials. 2021;265:120407.

[16] HuangZ, Callmann CE, WangS, et al. Rational vaccinology: harnessing nanoscale chemical design for cancer immunotherapy. ACS Cent Sci. 2022;8(6):692-704.

[17] TakeiS, Kawazoe A, ShitaraK. The new era of immunotherapy in gastric cancer. Cancers. 2022;14(4):1054.

[18] SmythEC, Nilsson M, GrabschHI, van GriekenNC, Lordick F. Gastric cancer. The Lancet. 2020;396(10251):635-648.

[19] IlsonDH. Advances in the treatment of gastric cancer. Curr Opin Gastroenterol. 2018;34(6):465-468.

[20] MaL, ZhuLJ, XuZJ, ShuYQ. Co-mutations in tumor immune microenvironment and immunotherapy. Chin Med J. 2021;134(9):1055-1057.

[21] GarrisCS, Arlauckas SP, KohlerRH, et al. Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γand IL-12. Immunity. 2018;49(6):1148-1161.e7.

[22] Vento-TormoR. Decoding foreign antigen tolerance. Science. 2023;379(6633):655.

[23] de VisserKE, JoyceJA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41(3):374-403.

[24] KarimiP, IslamiF, AnandasabapathyS, FreedmanND, Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 2014;23(5):700-713.

[25] Van der LeunAM, Thommen DS, SchumacherTN. CD8+T cell states in human cancer: insights from single-cell analysis. Nat Rev Cancer. 2020;20(4):218-232.

[26] XiaR, XuM, YangJ, Ma X. The role of Hedgehog and Notch signaling pathway in cancer. Mol Biomed. 2022;3(1):44.

[27] KwakY, KohJ, ParkY, et al. Differential prognostic impact of CD8+T cells based on human leucocyte antigen I and PD-L1 expression in microsatellite-unstable gastric cancer. Br J Cancer. 2020;122(9):1399-1408.

[28] ThompsonED, Zahurak M, MurphyA, et al. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut. 2017;66(5):794-801.

[29] SaitoT, Nishikawa H, WadaH, et al. Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers. Nature Med. 2016;22(6):679-684.

[30] XuH, JiaZ, LiuF, et al. Biomarkers and experimental models for cancer immunology investigation. MedComm. 2023;4(6):e437.

[31] KimEY, Abdul-Ghafar J, ChongY, YimK. Calculated tumor-associated neutrophils are associated with the Tumor-Stroma ratio and predict a poor prognosis in advanced gastric cancer. Biomedicines. 2022;10(3):708.

[32] FridlenderZG, SunJ, KimS, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell. 2009;16(3):183-194.

[33] WangT-t, ZhaoY-l, PengL-s, et al. Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway. Gut. 2017;66(11):1900-1911.

[34] YangS, ZouX, LiJ, et al. Immunoregulation and clinical significance of neutrophils/NETs-ANGPT2 in tumor microenvironment of gastric cancer. Front Immunol. 2022;13:1010434.

[35] RayesRF, Mouhanna JG, NicolauI, et al. Primary tumors induce neutrophil extracellular traps with targetable metastasis-promoting effects. JCI Insight. 2019;5(16):e128008.

[36] DemariaO, CornenS, DaëronM, MorelY, Medzhitov R, VivierE. Harnessing innate immunity in cancer therapy. Nature. 2019;574(7776):45-56.

[37] VitaleI, ManicG, CoussensLM, Kroemer G, GalluzziL. Macrophages and metabolism in the tumor microenvironment. Cell Metab. 2019;30(1):36-50.

[38] LiX, LiW, HouL, et al. A trial-based cost-effectiveness analysis of bevacizumab and chemotherapy versus chemotherapy alone for advanced nonsquamous non-small-cell lung cancer in China. Value Health Reg Issues. 2019;18:1-7.

[39] LinC, HeH, LiuH, et al. Tumour-associated macrophages-derived CXCL8 determines immune evasion through autonomous PD-L1 expression in gastric cancer. Gut. 2019;68(10):1764-1773.

[40] PengL-S, ZhangJ-Y, TengY-S, et al. Tumor-associated monocytes/macrophages impair NK-cell function via TGFβ1 in human gastric cancer. Cancer Immunol Res. 2017;5(3):248-256.

[41] WolfNK, Kissiov DU, RauletDH. Roles of natural killer cells in immunity to cancer, and applications to immunotherapy. Nat Rev Immunol. 2023;23(2):90-105.

[42] LeeS-C, Shimasaki N, LimJ, et al. Phase I trial of expanded, activated autologous NK-cell infusions with trastuzumab in patients with HER2-positive cancers. Cancer Immunol Res. 2020;26(17):4494-4502.

[43] IshigamiS, Natsugoe S, TokudaK, et al. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer. 2000;88(3):577-583.

[44] TakeuchiH, Maehara Y, TokunagaE, KogaT, KakejiY, SugimachiK. Prognostic significance of natural killer cell activity in patients with gastric carcinoma: a multivariate analysis. Am J Gastroenterol. 2001;96(2):574-578.

[45] XieM-z, TangYP, HuBL, LiKZ, LiJL, LiangXQ. Percentage of natural killer (NK) cells in peripheral blood is associated with prognosis in patients with gastric cancer: a retrospective study from a single center. Med Sci Monit. 2021;27:927464.

[46] KalluriR, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006;6(5):392-401.

[47] KuzetSE, Gaggioli C. Fibroblast activation in cancer: when seed fertilizes soil. Cell Tissue Res. 2016;365(3):607-619.

[48] YamaguchiH, SakaiR. Direct interaction between carcinoma cells and cancer associated fibroblasts for the regulation of cancer invasion. Cancers. 2015;7(4):2054-2062.

[49] GaoC, LiuF, YeQ, GuoA. Cancer-associated fibroblasts affect tumor metabolism and immune microenvironment in gastric cancer and identification of its characteristic genes. J Oncol. 2023;2023:1424589.

[50] JayasingamSD, Citartan M, ThangTH, Mat ZinAA, AngKC, Ch’ngES. Evaluating the polarization of tumor-associated macrophages into M1 and M2 phenotypes in human cancer tissue: technicalities and challenges in routine clinical practice. Front Oncol. 2019;9:1512.

[51] LuY, LiD, CaoY, et al. A genomic signature reflecting fibroblast infiltration into gastric cancer is associated with prognosis and treatment outcomes of immune checkpoint inhibitors. Front Cell Dev Biol. 2022;10:862294.

[52] LiuX, YaoL, QuJ, et al. Cancer-associated fibroblast infiltration in gastric cancer: the discrepancy in subtypes pathways and immunosuppression. J Transl Med. 2021;19(1):325.

[53] MatlungHL, Szilagyi K, BarclayNA, van den BergTK. The CD47-SIRPαsignaling axis as an innate immune checkpoint in cancer. Immunol Rev. 2017;276(1):145-164.

[54] CarlinoMS, LarkinJ, LongGV. Immune checkpoint inhibitors in melanoma. The Lancet. 2021;398(10304):1002-1014.

[55] RhaSY, OhDY, YañezP, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(11):1181-1195.

[56] LamLL, Pavlakis N, ShitaraK, et al. INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory advanced gastro-oesophageal cancer (AGOC): a study by the australasian gastro-intestinal trials group (AGITG). BMC Cancer. 2023;23(1):180.

[57] RovielloG, CoronaSP, D’AngeloA, RoselliniP, NobiliS, MiniE. Immune checkpoint inhibitors in pre-treated gastric cancer patients: results from a literature-based meta-analysis. Int J Mol Sci. 2020;21(2):448.

[58] XieT, ZhangZ, ZhangX, Qi C, ShenL, PengZ. Appropriate PD-L1 cutoff value for gastric cancer immunotherapy: a systematic review and meta-analysis. Front Oncol. 2021;11:646355.

[59] PietrantonioF, RandonG, Di BartolomeoM, et al. Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials. ESMO Open. 2021;6(1):100036.

[60] QinH, LiuF, ZhangY, et al. Comparison of neoadjuvant immunotherapy versus routine neoadjuvant therapy for patients with locally advanced esophageal cancer: a systematic review and meta-analysis. Front Immunol. 2023;14:1108213.

[61] XuH, LiT, ShaoG, et al. Evaluation of neoadjuvant immunotherapy plus chemotherapy in Chinese surgically resectable gastric cancer: a pilot study by meta-analysis. Front Immunol. 2023;14:1193614.

[62] SagarJ, ChaibB, SalesK, Winslet M, SeifalianA. Role of stem cells in cancer therapy and cancer stem cells: a review. Cancer Cell Int. 2007;7:9.

[63] ZhaoL, CaoYJ. Engineered T cell therapy for cancer in the clinic. Front Immunol. 2019;10:2250.

[64] QiC, GongJ, LiJ, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nature Med. 2022;28(6):1189-1198.

[65] YeZ, LiZ, JinH, QianQ. Therapeutic cancer vaccines. Adv Exp Med Biol. 2016;909:139-167.

[66] HeinKZ, YaoS, FuS. Wilms’tumor 1 (WT1): the vaccine for cancer. J Immunother Precis Oncol. 2020;3(4):165-171.

[67] WangX, LiuY, DiaoY, et al. Gastric cancer vaccines synthesized using a TLR7 agonist and their synergistic antitumor effects with 5-fluorouracil. J Transl Med. 2018;16(1):120.

[68] LeidnerR, ConlonK, McNeelDG, et al. First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors. J Immunother Cancer. 2023;11(10):e007725.

[69] PaikJ. Nivolumab plus relatlimab: first approval. Drugs. 2022;82(8):925-931.

[70] ProvencioM, NadalE, González-LarribaJL, et al. Perioperative nivolumab and chemotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2023;389(6):504-513.

[71] AtkinsMB, LeeSJ, ChmielowskiB, et al. Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq Trial-ECOG-ACRIN EA6134. J Clin Oncol. 2023;41(2):186-197.

[72] JanjigianYY, Shitara K, MoehlerM, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. The Lancet. 2021;398(10294):27-40.

[73] TsimberidouAM, Fountzilas E, NikanjamM, KurzrockR. Review of precision cancer Medicine: evolution of the treatment paradigm. Cancer Treat Rev. 2020;86:102019.

[74] MoehlerM, Wyrwicz L, ChenC, et al. O-10 health-related quality of life (HRQOL) in patients with advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma cancer (GC/GEJC/EAC):36-month results of CheckMate 649 nivolumab plus chemotherapy (N+C) versus chemo (C). Ann Oncol. 2023;34:S185.

[75] ShenL, BaiY, LinX, et al. First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis with 3-year follow-up. J Clin Oncol. 2023;41(4_suppl):353.

[76] JanjigianYY, Shitara K, MoehlerMH, et al. Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC):3-year follow-up from CheckMate 649. J Clin Oncol. 2023;41(16_suppl):4025.

[77] YoonJ, KimT-Y, OhD-Y. Recent progress in immunotherapy for gastric cancer. J Gastric Cancer. 2023;23(1):207.

[78] JiangH, ShiZ, WangP, et al. Claudin18.2-specific chimeric antigen receptor engineered T cells for the treatment of gastric cancer. J Natl Cancer Inst. 2019;111(4):409-418.

[79] AhnS, LeeJ, HongM, et al. FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival. Mod Pathol. 2016;29(9):1095-1103.

[80] SmythEC, ChaoJ, MuroK, et al. Trial in progress: phase 3 study of bemarituzumab + mFOLFOX6 versus placebo + mFOLFOX6 in previously untreated advanced gastric or gastroesophageal junction (GEJ) cancer with FGFR2b overexpression (FORTITUDE-101). J Clin Oncol. 2022;40(16_suppl):TPS4164.

[81] TanDSW, FelipE, de CastroG, et al. Canakinumab versus placebo in combination with first-line pembrolizumab plus chemotherapy for advanced non-small-cell lung cancer: results from the CANOPY-1 trial. J Clin Oncol. 2024;42(2):192-204.

[82] LlovetJM, KudoM, MerleP, et al. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(12):1399-1410.

[83] FuchsCS, DoiT, JangRW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018;4(5):e180013.

[84] ShitaraK, Özgüroğlu M, BangYJ, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. The Lancet. 2018;392(10142):123-133.

[85] FuchsCS, Özgüroğlu M, BangYJ, et al. Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer:2-year update of the randomized phase 3 KEYNOTE-061 trial. Gastric Cancer. 2022;25(1):197-206.

[86] ShitaraK, Özgüroğlu M, BangYJ, et al. Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma. Ann Oncol. 2021;32(9):1127-1136.

[87] RhaSY, Wyrwicz L, Yanez WeberPE, et al. KEYNOTE-859 study of pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: outcomes in the protocol-specified PD-L1-selected populations. J Clin Oncol. 2023;41(16):4014.

[88] JanjigianYY, MaronSB, ChatilaWK, et al. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2020;21(6):821-831.

[89] JanjigianYY, Kawazoe A, YañezP, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021;600(7890):727-730.

[90] JanjigianYY, Kawazoe A, BaiY, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. The Lancet. 2023;402(10418):2197-2208.

[91] ShitaraK, RhaSY, WyrwiczLS, et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastrooesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol. 2024;25(2):212-224.

[92] ZhangX, ZhengJ, NiuY, et al. Long-term survival in extensive-stage small-cell lung cancer treated with different immune checkpoint inhibitors in multiple-line therapies: a case report and literature review. Front Immunol. 2022;13:1059331.

[93] ShengX, YanX, ChiZ, et al. Axitinib in combination with toripalimab, a humanized immunoglobulin G4 monoclonal antibody against programmed cell Death-1, in patients with metastatic mucosal melanoma: an open-label phase IB trial. J Clin Oncol. 2019;37(32):2987-2999.

[94] TangB, YanX, ShengX, et al. Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients. J Hematol Oncol. 2019;12(1):7.

[95] WangFH, WeiXL, FengJ, et al. Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial (POLARIS-02). J Clin Oncol. 2021;39(7):704-712.

[96] MaiHQ, ChenQY, ChenD, et al. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. Nature Med. 2021;27(9):1536-1543.

[97] JiangZ, XieY, WangB, et al. Oxaliplatin and capecitabine (XELOX) plus toripalimab as perioperative treatment for locally advanced gastric or gastro-esophageal junction adenocarcinoma (Neo-Capture): a single-arm, phase 2 study. J Clin Oncol. 2022;40(16_suppl):e16001.

[98] LiH, DengJ, GeS, et al. Phase II study of perioperative toripalimab in combination with FLOT in patients with locally advanced resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma. J Clin Oncol. 2021;39(15_suppl):4050.

[99] YuanS, NieR-C, JinY, et al. Perioperative PD-1 antibody toripalimab plus SOX or XELOX chemotherapy versus SOX or XELOX alone for locally advanced gastric or gastro-oesophageal junction cancer: results from a prospective, randomized, open-label, phase II trial. J Clin Oncol. 2023;41(16_suppl):4001.

[100] ZhangT, YuD, WangJ, et al. 1403P toripalimab combined with nab-paclitaxel/docetaxel as second-line treatment in patients with advanced gastric cancer: preliminary results from a single-arm, open-label phase II trial. Ann Oncol. 2021;32:S1057-S1058.

[101] RenS, ChenJ, XuX, et al. Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-Sq): a phase 3 trial. J Thorac Oncol. 2022;17(4):544-557.

[102] YangY, QuS, LiJ, et al. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2021;22(8):1162-1174.

[103] ZhouC, ChenG, HuangY, et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. Lancet Respir Med. 2021;9(3):305-314.

[104] QinS, ChanSL, GuS, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. The Lancet. 2023;402(10408):1133-1146.

[105] PengZ, WeiJ, WangF, et al. Camrelizumab combined with chemotherapy followed by camrelizumab plus apatinib as first-line therapy for advanced gastric or gastroesophageal junction adenocarcinoma. Clin Cancer Res. 2021;27(11):3069-3078.

[106] QiuM, WangD-S, SunY-T, Zhao Q, GuanW-L, XuR. PD-1 antibody (Camrelizumab) for metastatic EBV positive gastric cancer: a prospective single-arm, open-label, phase 2 trial. J Clin Oncol. 2021;39(15_suppl):e16014.

[107] LiuY, HanG, LiH, et al. Camrelizumab combined with FLOFOX as neoadjuvant therapy for resectable locally advanced gastric and gastroesophageal junction adenocarcinoma: updated results of efficacy and safety. J Clin Oncol. 2021;39(15_suppl):4036.

[108] LiS, YuW, XieF, et al. Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer. Nat Commun. 2023;14(1):8.

[109] NiB, XiaX, GuanY, et al. A single-center, prospective, single-arm, phase II trial to evaluate the adjuvant efficacy of camrelizumab with docetaxel plus S-1 for stage III (PD-L1+/dMMR/EBV+) gastric cancer after D2 resection. J Clin Oncol. 2023;41(16_suppl):e16089.

[110] ChenYX, YangP, DuSS, et al. Stereotactic body radiotherapy combined with sintilimab in patients with recurrent or oligometastatic hepatocellular carcinoma: a phase II clinical trial. World J Gastroenterol. 2023;29(24):3871-3882.

[111] LuS, WuL, JianH, et al. Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2023;11(7):624-636.

[112] FuQ, ChenY, HuangD, et al. Sintilimab plus modified FOLFIRINOX in metastatic or recurrent pancreatic cancer: the randomized phase II CISPD3 trial. Ann Surg Oncol. 2023;30(8):5071-5080.

[113] WeiJ, LuX, LiuQ, et al. Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm phase 2 trial. Nat Commun. 2023;14(1):4904.

[114] JiangH, YuX, LiN, et al. Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study. J Immunother Cancer. 2022;10(3):e003635.

[115] XuJ, JiangH, PanY, et al. Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial. JAMA. 2023;330(21):2064-2074.

[116] ZhangL, WangW, GeS, et al. Sintilimab plus apatinib and chemotherapy as second /third-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma: a prospective, Single-Arm, phase II trial. BMC Cancer. 2023;23(1):211.

[117] CaiT, LiangL, ZhaoX, Lin C, LiD, ZhengJ. Comparative efficacy and tolerability of first-line treatments for untreated, HER2-negative, advanced gastric cancer: systematic review and network meta-analysis. Crit Rev Oncol Hematol. 2024;193:104216.

[118] LuS, WangJ, YuY, et al. Tislelizumab plus chemotherapy as first-line treatment for locally advanced or metastatic nonsquamous NSCLC (RATIONALE 304): a randomized phase 3 trial. J Thorac Oncol. 2021;16(9):1512-1522.

[119] ZhouC, HuangD, FanY, et al. Tislelizumab versus docetaxel in patients with previously treated advanced NSCLC (RATIONALE-303): a phase 3, open-label, randomized controlled trial. J Thorac Oncol. 2023;18(1):93-105.

[120] WangJ, LuS, YuX, et al. Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2021;7(5):709-717.

[121] WangJ, SunY, WangF, et al. 1538P A phase II study to evaluate the efficacy and safety of tislelizumab combined with chemotherapy (cis-platinum plus albumin-paclitaxel/paclitaxel) in neoadjuvant treatment of locally advanced oesophageal squamous cell carcinoma. Ann Oncol. 2023;34:S865S865.

[122] ShiJW, ZhouY, WuS. Clinical efficacy and safety of adjuvant immunotherapy (Tislelizumab) plus chemotherapy vs. adjuvant chemotherapy alone in lymph node-positive patients with gastric cancer after D2 radical resection: a prospective, 2-arm, phase II study. Eur Rev Med Pharmacol Sci. 2023;27(21):10472-10480.

[123] MoehlerMH, KatoK, ArkenauH-T, et al. Rationale 305: phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC). J Clin Oncol. 2023;41(4_suppl):286.

[124] OhD-Y, HeAR, QinS, et al. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. J Clin Oncol. 2022;40(4_suppl):378.

[125] JanjigianYY, Al-Batran SE, WainbergZA, et al. LBA73 pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): interim results of the global, phase III MATTERHORN study. Ann Oncol. 2023;34:S1315-S1316.

[126] KimT-Y, YoonJ, LeeD-W, et al. A phase II biomarker-oriented study to evaluate paclitaxel, olaparib, and durvalumab combination in patients with advanced gastric cancer. J Clin Oncol. 2023;41(4_suppl):404.

[127] LeeK-W, KimHK, RyuM-H, et al. Phase II study of the combination of durvalumab, tremelimumab, and paclitaxel as second-line chemotherapy in biomarker-selected patients with metastatic gastric cancer. J Clin Oncol. 2023;41(4_suppl):401.

[128] SzabadosB, KockxM, AssafZJ, et al. Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder. Eur Urol. 2022;82(2):212-222.

[129] FelipE, Altorki N, ZhouC, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. The Lancet. 2021;398(10308):1344-1357.

[130] RuggieriAN, Yarchoan M, GoyalS, et al. Combined MEK/PD-L1 inhibition alters peripheral cytokines and lymphocyte populations correlating with improved clinical outcomes in advanced biliary tract cancer. Clin Cancer Res. 2022;28(19):4336-4345.

[131] ChalabiM, Verschoor YL, Van De HaarJ, et al. 1219P neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction (G/GEJ) adenocarcinoma: the PANDA study. Ann Oncol. 2022;33:S1106.

[132] GordonA, Challoner B, AthaudaA, et al. Primary results of the ICONIC phase 2 trial of perioperative FLOT plus avelumab (FLOT-A) in operable oesophagogastric adenocarcinoma (OGA). J Clin Oncol. 2023;41(4_suppl):446.

[133] GerlingerM, GordonA, BarberLJ, et al. Abstract 5591: circulating tumor DNA for recurrence prediction and efficacy analysis in the ICONIC trial of peri-operative FLOT and avelumab (PD-L1) in localized esophago-gastric adenocarcinoma. Cancer Res. 2023;83(7_suppl):5591.

[134] HuangH, TaoR, HaoS, et al. Sugemalimab monotherapy for patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (GEMSTONE-201): results from a single-arm, multicenter, phase II study. J Clin Oncol. 2023;41(16):3032-3041.

[135] ZhouC, WangZ, SunM, et al. A protocol pre-specified interim overall survival (OS) analysis of GEMSTONE-302: a phase 3 study of sugemalimab (suge) versus placebo plus platinum-based chemotherapy (chemo) as first-line (1L) treatment for patients (pts) with metastatic non-small cell lung cancer (NSCLC). J Clin Oncol. 2022;40(16_suppl):9027.

[136] ZhangX, WangJ, WangG, et al. LBA79 GEMSTONE-303: prespecified progression-free survival (PFS) and overall survival (OS) final analyses of a phase III study of sugemalimab plus chemotherapy vs placebo plus chemotherapy in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. Ann Oncol. 2023;34:S1319.

[137] LarkinJ, Chiarion-Sileni V, GonzalezR, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23-34.

[138] ShitaraK, AjaniJA, MoehlerM, et al. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature. 2022;603(7903):942-948.

[139] AndréT, Tougeron D, PiessenG, et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study. J Clin Oncol. 2023;41(2):255-265.

[140] TintelnotJ, SteinA, PascholdL, et al. Final survival results of ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive esophago gastric adenocarcinoma: the randomized AIO INTEGA trial. J Clin Oncol. 2023;41(16_suppl):4026.

[141] JiJ, ShenL, LiZ, et al. Cadonilimab plus chemotherapy versus chemotherapy as first-line treatment for unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (COMPASSION-15): a randomized, double-blind, phase 3 trial. 2024 AACR Annual Meetingannual meeting. Abstract CT006. Presented April 7, 2024.

[142] RohrbergKS, Brandão M, Castanon AlvarezE, et al. Safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of AZD2936, a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-experienced advanced/metastatic non-small-cell lung cancer (NSCLC): first report of ARTEMIDE-01. J Clin Oncol. 2023;41(16_suppl):9050.

[143] NeelapuSS, LockeFL, BartlettNL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531-2544.

[144] PanJ, TangK, LuoY, et al. Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2023;24(11):1229-1241.

[145] ZhangX, YangJ, LiJ, et al. Analysis of 60 patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma treated with CD7-targeted chimeric antigen receptor-T cell therapy. Am J Hematol. 2023;98(12):1898-1908.

[146] HuangR, WenQ, ZhangX. CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022. J Hematol Oncol. 2023;16(1):35.

[147] MaalejKM, MerhiM, InchakalodyVP, et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol Cancer. 2023;22(1):20.

[148] HuoY, ZhangH, SaL, et al. M1 polarization enhances the antitumor activity of chimeric antigen receptor macrophages in solid tumors. J Transl Med. 2023;21(1):225.

[149] SchepisiG, GianniC, PalleschiM, et al. The new frontier of immunotherapy: chimeric antigen receptor T (CAR-T) cell and macrophage (CAR-M) therapy against breast cancer. Cancers. 2023;15(5):1597.

[150] PanQ, WengD, LiuJ, et al. Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A∗02:01 patients with advanced soft tissue sarcoma. Cell Rep Med. 2023;4(8):101133.

[151] PangZ, LuM, ZhangY, et al. Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges. Biomark Res. 2023;11(1):104.

[152] PiroozkhahM, Gholinezhad Y, PiroozkhahM, ShamsE, Nazemalhosseini-Mojarad E. The molecular mechanism of actions and clinical utilities of tumor infiltrating lymphocytes in gastrointestinal cancers: a comprehensive review and future prospects toward personalized medicine. Front Immunol. 2023;14:1298891.

[153] ZhaoY, DengJ, RaoS, et al. Tumor infiltrating lymphocyte (TIL) therapy for solid tumor treatment: progressions and challenges. Cancers. 2022;14(17):4160.

[154] VishweshwaraiahYL, Dokholyan NV. mRNA vaccines for cancer immunotherapy. Front Immunol. 2022;13:1029069.

[155] JiangJ, MeiJ, YiS, et al. Tumor associated macrophage and microbe: the potential targets of tumor vaccine delivery. Adv Drug Deliv Rev. 2022;180:114046.

[156] GuoZ, YuanY, ChenC, et al. Durable complete response to neoantigen-loaded dendritic-cell vaccine following anti-PD-1 therapy in metastatic gastric cancer. NPJ Precis Oncol. 2022;6(1):34.

[157] HouW, ZhaoY, ZhuH. Predictive biomarkers for immunotherapy in gastric cancer: current status and emerging prospects. Int J Mol Sci. 2023;24(20):15321.

[158] BagchiS, YuanR, EnglemanEG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol: Mech Dis. 2021;16:223-249.

[159] NakajimaTE, Kadowaki S, MinashiK, et al. Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer. Clin Cancer Res. 2021;27(4):1029-1036.

[160] ZhaoJJ, YapDWT, ChanYH, et al. Low programmed death-ligand 1-expressing subgroup outcomes of first-line immune checkpoint inhibitors in gastric or esophageal adenocarcinoma. J Clin Oncol. 2022;40(4):392-402.

[161] LengyelCG, Hussain S, TrapaniD, et al. The emerging role of liquid biopsy in gastric cancer. J Clin Med. 2021;10(10):2108.

[162] DavisAA, PatelVG. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):278.

[163] Schoemig-MarkiefkaB, Eschbach J, ScheelAH, et al. Optimized PD-L1 scoring of gastric cancer. Gastric Cancer. 2021;24(5):1115-1122.

[164] MaioM, Ascierto PA, ManzyukL, et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol. 2022;33(9):929-938.

[165] AddeoA, Friedlaender A, BannaGL, WeissGJ. TMB or not TMB as a biomarker: that is the question. Crit Rev Oncol Hematol. 2021;163:103374.

[166] LeeKW, Van Cutsem E, BangYJ, et al. Association of tumor mutational burden with efficacy of pembrolizumab±chemotherapy as first-line therapy for gastric cancer in the phase III KEYNOTE-062 study. Clin Cancer Res. 2022;28(16):3489-3498.

[167] McGrailDJ, Pilié PG, RashidNU, et al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol. 2021;32(5):661-672.

[168] KimSY, ParkC, KimHJ, et al. Deregulation of immune response genes in patients with Epstein-Barr virus-associated gastric cancer and outcomes. Gastroenterology. 2015;148(1):137-147.e9.

[169] SalnikovM, Prusinkiewicz MA, LinS, GhasemiF, Cecchini MJ, MymrykJS. Tumor-infiltrating T cells in EBV-associated gastric carcinomas exhibit high levels of multiple markers of activation, effector gene expression, and exhaustion. Viruses. 2023;15(1):176.

[170] KimST, Cristescu R, BassAJ, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nature Med. 2018;24(9):1449-1458.

[171] SunYT, GuanWL, ZhaoQ, et al. PD-1 antibody camrelizumab for Epstein-Barr virus-positive metastatic gastric cancer: a single-arm, open-label, phase 2 trial. Am J Cancer Res. 2021;11(10):5006-5015.

[172] NakayamaA, AbeH, KunitaA, et al. Viral loads correlate with upregulation of PD-L1 and worse patient prognosis in Epstein-Barr virus-associated gastric carcinoma. PLoS One. 2019;14(1):e0211358.

[173] Ramos-CasalsM, Brahmer JR, CallahanMK, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6(1):38.

[174] BhanderiH, KhalidF, BodlaZH, Muhammad T, DuD, MeghalT. Autoimmune diabetes from pembrolizumab: a case report and review of literature. World J Clin Oncol. 2023;14(11):535-543.

[175] SebestyénE, Major N, BodokiL, et al. Immune-related adverse events of anti-PD-1 immune checkpoint inhibitors: a single center experience. Front Oncol. 2023;13:1252215.

[176] MaggioreU, Pascual J. The bad and the good news on cancer immunotherapy: implications for organ transplant recipients. Adv Chronic Kidney Dis. 2016;23(5):312-316.

[177] ButteMJ, KeirME, PhamduyTB, Sharpe AH, FreemanGJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007;27(1):111-122.

[178] BębnowskaD, Grywalska E, Niedźwiedzka-Rystwej P, et al. CAR-T cell therapy-an overview of targets in gastric cancer. J Clin Med. 2020;9(6):1894.

[179] SternerRC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69.

[180] ZhangX, ZhuL, ZhangH, Chen S, XiaoY. CAR-T cell therapy in hematological malignancies: current opportunities and challenges. Front Immunol. 2022;13:927153.

[181] ChohanKL, Siegler EL, KenderianSS. CAR-T cell therapy: the efficacy and toxicity balance. Curr Hematol Malig Rep. 2023;18(2):9-18.

[182] ChampiatS, DercleL, AmmariS, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by Anti-PD-1/PD-L1. Clin Cancer Res. 2017;23(8):1920-1928.

[183] KimJY, LeeKH, KangJ, et al. Hyperprogressive disease during anti-PD-1 (PDCD1)/PD-L1 (CD274) therapy: a systematic review and meta-analysis. Cancers. 2019;11(11):1699.

[184] RefaeS, GalJ, BrestP, et al. Hyperprogression under immune checkpoint inhibitor: a potential role for germinal immunogenetics. Sci Rep. 2020;10(1):3565.

[185] KimCG, KimKH, PyoKH, et al. Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer. Ann Oncol. 2019;30(7):1104-1113.

[186] Saâda-BouzidE, Defaucheux C, KarabajakianA, et al. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2017;28(7):1605-1611.

[187] KatoS, Goodman A, WalavalkarV, BarkauskasDA, Sharabi A, KurzrockR. Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res. 2017;23(15):4242-4250.

[188] KamadaT, Togashi Y, TayC, et al. PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc Natl Acad Sci USA. 2019;116(20):9999-10008.

[189] RobertC, LongGV, BradyB, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320-330.

[190] KatzSI, HammerM, BagleySJ, et al. Radiologic pseudoprogression during anti-PD-1 therapy for advanced non-small cell lung cancer. J Thorac Oncol. 2018;13(7):978-986.

[191] NecchiA, JosephRW, LoriotY, et al. Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study. Ann Oncol. 2017;28(12):3044-3050.

[192] Di GiacomoAM, Danielli R, GuidoboniM, et al. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother. 2009;58(8):1297-1306.

[193] CohenSA, LiuMC, AleshinA. Practical recommendations for using ctDNA in clinical decision making. Nature. 2023;619(7969):259-268.

[194] OttPA, BangYJ, Piha-PaulSA, et al. T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. J Clin Oncol. 2019;37(4):318-327.

[195] DongH, StromeSE, SalomaoDR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nature Med. 2002;8(8):793-800.

[196] KimTK, HerbstRS, ChenL. Defining and understanding adaptive resistance in cancer immunotherapy. Trends Immunol. 2018;39(8):624-631.

[197] ContiL, RegisG, LongoA, et al. In the absence of IGF-1 signaling, IFN-γsuppresses human malignant T-cell growth. Blood. 2007;109(6):2496-2504.

[198] HanJ, WuM, LiuZ. Dysregulation in IFN-γsignaling and response: the barricade to tumor immunotherapy. Front Immunol. 2023;14:1190333.

[199] LiJ, ZhangH, BeiS, et al. Disruption of Wnt/β-catenin pathway elevates the sensitivity of gastric cancer cells to PD-1 antibody. Current Molecular Pharmacology. 2022;15(3):557-569.

[200] MpakaliA, Stratikos E. The role of antigen processing and presentation in cancer and the efficacy of immune checkpoint inhibitor immunotherapy. Cancers. 2021;13(1):134.

[201] IwasakiA, Shinozaki-Ushiku A, KunitaA, et al. Human leukocyte antigen class I deficiency in gastric carcinoma: an adaptive immune evasion strategy most common in microsatellite instable tumors. Am J Surg Pathol. 2021;45(9):1213-1220.

[202] YuanXL, ChenL, LiMX, et al. Elevated expression of Foxp3 in tumor-infiltrating Treg cells suppresses T-cell proliferation and contributes to gastric cancer progression in a COX-2-dependent manner. Clin Immunol. 2010;134(3):277-288.

[203] FearonDT, Pommier A, LudwigM, TuvesonD. Abstract IA11: T cell exclusion in pancreatic ductal adenocarcinoma: the FAP+cancer-associated fibroblast and CXCL12. Cancer Immunol Res. 2015;3(10_suppl):IA11.

[204] AguileraTA, Giaccia AJ. Molecular pathways: oncologic pathways and their role in T-cell exclusion and immune Evasion-A new role for the AXL receptor tyrosine kinase. Clin Cancer Res. 2017;23(12):2928-2933.

[205] HeW, ZhangH, HanF, et al. CD155T/TIGIT signaling regulates CD8(+) T-cell metabolism and promotes tumor progression in human gastric cancer. Cancer Res. 2017;77(22):6375-6388.

[206] ZhangY, GuanX, JiangP. Cytokine and chemokine signals of T-cell exclusion in tumors. Front Immunol. 2020;11:594609.

[207] KangY-K, Terashima M, KimY-W, et al. Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2024;9(8):705-717.

[208] LiC, ShiZ, ZhengY, et al. 1512MO perioperative camrelizumab (C) combined with rivoceranib (R) and chemotherapy (chemo) versus chemo for locally advanced resectable gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: the first interim analysis of a randomized, phase III trial (DRAGON IV). Ann Oncol. 2023;34:S852.

[209] AndréT, Tougeron D, PiessenG, et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study. J Clin Oncol. 2023;41(2):255-265.

[210] PietrantonioF, Raimondi A, LonardiS, et al. INFINITY: a multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC). J Clin Oncol. 2023;41(4_suppl):358.

[211] GaoF, YangC. Anti-VEGF/VEGFR2 monoclonal antibodies and their combinations with PD-1/PD-L1 inhibitors in clinic. Curr Cancer Drug Targets. 2020;20(1):3-18.

[212] MartinKS. Microtubule-depolymerizing agents potentiate anti-tumor immunity by stimulation of dendritic cells. University_of_Basel;2015.

[213] ChenH, JiangT, LinF, et al. PD-1 inhibitor combined with apatinib modulate the tumor microenvironment and potentiate anti-tumor effect in mice bearing gastric cancer. Int Immunopharmacol. 2021;99:107929.

[214] FezzaM, MoussaM, AounR, Haber R, HilalG. DKK1 promotes hepatocellular carcinoma inflammation, migration and invasion: implication of TGF-β1. PLoS One. 2019;14(9):e0223252.

[215] KlempnerSJ, SonbolBB, WainbergZA, et al. A phase 2 study (DisTinGuish) of DKN-01 in combination with tislelizumab +chemotherapy as first-line (1L) therapy in patients with advanced gastric or GEJ adenocarcinoma (GEA). J Clin Oncol. 2023;41(16_suppl):40274027.

[216] ChenZH, LinL, WuCF, LiCF, XuRH, SunY. Artificial intelligence for assisting cancer diagnosis and treatment in the era of precision medicine. Cancer Commun. 2021;41(11):1100-1115.

[217] LealA, van Grieken NCT, PalsgroveDN, et al. White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer. Nat Commun. 2020;11(1):525.

[218] JinY, ChenDL, WangF, et al. The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors. Mol Cancer. 2020;19(1):154.

[219] WangY, ZhangH, LiuC, et al. Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts. J Hematol Oncol. 2022;15(1):111.

[220] UpadhayaS, Neftelino ST, HodgeJP, OlivaC, Campbell JR, YuJX. Combinations take centre stage in PD1/PDL1 inhibitor clinical trials. Nat Rev Drug Discovery. 2021;20(3):168-169.

[221] JanjigianYY, AjaniJA, MoehlerM, et al. LBA7 Nivolumab (NIVO) plus chemotherapy (Chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 study. Ann Oncol. 2021;32:S1329-S1330.

RIGHTS & PERMISSIONS

2024 The Author(s). MedComm – Oncology published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).